It's a toughie that's for sure, the finance issue is the main problem. The market rightly doesn't see much credible pathway out of this company's current predicament. If the company had enough resources to complete the necessary trials then the delay wouldn't be so critical. It has become very critical indeed and it is now last chance-saloon stuff. It's hard to see where they get the financing from or who they partner with to finally (hopefully) achieve CE/FDA mark approval. The decision to not conduct a proper double blind trial all those years ago may prove to be the key decision that killed this company and it's potentially pretty useful 'device'. It's a shame but not much can be done now.
I'd buy if they had a credible story about how they are going to resource the necessary trials, but none of the announcements have given any comfort on that front. Also where is the pipeline of other products to reduce risk and increase shareholder value? Why has this company only 'produced' Vitrogro in over a decade of operation? From their website: 'The company also has a licence for commercialisation of various patent families related to wound healing and other therapeutic uses'....where are these other products?
TIS Price at posting:
3.5¢ Sentiment: None Disclosure: Held
